Logo

Boehringer Ingelheim (BI) and Bioharmony Therapeutics Collaborates to Develop Bacteriophage Lysins

Share this

Boehringer Ingelheim (BI) and Bioharmony Therapeutics Collaborates to Develop Bacteriophage Lysins

Shots:
  • BI to get rights to develop and commercialize bacteriophage lysins using Bioharmony ‘s technology for multi-drug resistant (MDR) Acinetobacter infections caused by Acinetobacter baumannii
  • The focus of the collaboration is to develop anti-microbial therapies against multi-drug resistant bacterial infections
  • Lysins are enzymes made of bacteriophages involved in breaching the bacterial cell wall in seconds- further killing the targeted bacteria
Ref: Businesswire | Image: BigChem

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions